| request information: |
|
| Catalog Code: | NB100-79920 |
| Product Name: | Cyclin D1 Antibody |
| Product Description: | Rabbit Monoclonal anti-Cyclin D1 (EPR2241IHC) |
| Clone: | EPR2241IHC |
| Clonality: | Monoclonal |
| ListPrice: | 320 |
| Reference Sequence: | P24385 |
| Immunogen: | A synthetic peptide corresponding to residues near the C-terminus of human Cyclin D1 was used as an immunogen. |
| Specificity: | A synthetic peptide corresponding to residues near the C-terminus of human Cyclin D1 was used as an immunogen. |
| Cross Reactivity: | This antibody is reactive against Human, Mouse, Rat |
| Packaging: | 0.1 ml Rabbit ascites |
| Uses: | This antibody is useful for: Western Blot, immunohistochemistry, Immunocytochemistry, immunoprecipitation |
| Background: | Cyclin D1 belongs to the Cyclin D family. Cyclin D1 is required for the cell cycle G1/S transition (1). Cyclin D1 forms a serine/threonine kinase holoenzyme complex with and functions as a regulatory subunit of CDK4 or CDK6. Cyclin D1 also phosphorylates and inactivates the retinoblastoma protein and promotes progression through the G1/S phase (2-3). Amplification or overexpression of cyclin D1 plays a pivotal role in the development of various human cancers including parathyroid adenoma, breast cancer, colon cancer, lymphoma, melanoma, and prostate cancer (4). Over-expression of cyclin D1 is known to correlate with the early onset of cancer and risk of tumor progression and metastasis (5). Cyclin D1 also associates with, and regulates the activity of transcription factors, coactivators and corepressors that govern histone acetylation and chromatin remodeling proteins (6-7) |
| Storage: | Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles. |
| Isotype: | IgG |
| Host Name: | Rabbit |
| Application Summary: | Western Blot 1:10000-50000, immunohistochemistry 1:100-250, Immunocytochemistry 1:100-250, immunoprecipitation 1:40 |
| Species Summary: | Hu, Mu, Rt |
| Package Size: | 0.1 ml |
| Preservative: | 0.01% Sodium Azide |
| General References: | 1. Inaba et al. Genomics 13:565-574, 1992 2. Sherr CJ Canc Res 60:3689-3695, 2000 3. Baldin et al. Genes Dev 7:812-821, 1993 4. Bala S, Peltomaki P Cancer Res 61:6042-6045, 1999 5. Motokura T, Arnold A Genes Chrom. Canc. 7:89-95, 1993 6. Wang et al. Cancer Treat Res 119:217-237, 2004 7. Neumeister et al. Mol Biol Cell 14:2005-201 |
order or
more information: | company product webpage |
|